Secretome of cardiovascular progenitor cells : first-in Human treatment for…
Validate targets, mechanisms and translational rationale before committing development resources.
Offer overview
What this offer helps you achieve
Validate targets, mechanisms and translational rationale before committing development resources.
Scientific and technical scope
A new therapy developed by Philippe Menasché: A cardiovascular cell-derived secretome for heart failure patients is produced at the MEARY Center in collaboration with FUJIFILM Cellular Dynamics for GMP IPS cell lines. Stage : First-in-man use of a cardiovascular cell-derived secretome in heart failure. Case report reported in Lancet eBioMedicine, Volume 103, 105145. Assistance Publique - Hôpitaux de Paris Clinical trials NCT05774509
Capabilities mobilised
Therapeutic areasTherapeutic target discovery
Application fields
Cardiology
Discuss this offer
Could this capability strengthen your R&D programme?
Present your scientific, technical or clinical need and identify the most relevant route to collaboration.
Continue exploring
Related expertise for your programme
Offers selected through shared capabilities, application fields or institute expertise.
